Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source explores injectable minoxidil as a hair loss treatment, noting its enhanced bioavailability but also the potential for adverse effects and higher costs compared to other formulations, with a call for further research on its efficacy and access relative to alternatives.

This article highlights the need for a comprehensive review of injectable minoxidil for hair loss, as existing treatments primarily focus on topical and oral forms of the medication.

This study reviewed the evidence on minoxidil's effectiveness for androgenetic alopecia, finding that 5% topical minoxidil is the most effective monotherapy for men, while 2% is similarly effective for women. Genetic markers can predict response, and new formulations like foam and gel improve tolerability.

This study explored the effectiveness of injectable treatments for androgenetic alopecia, finding that dutasteride and growth factor formulations achieved clinically significant results compared to controls like saline and topical minoxidil, within selected trials from 2000 to 2023.

This review provides a comprehensive look at injectable treatments like PRP, stem cells, and exosomes for hair regrowth, highlighting their potential to minimize systemic and localized side effects associated with conventional medications, and improve patient care by stimulating natural hair growth.

In this systematic review, researchers found that injectable therapies, including agents like dutasteride and multivitamin formulations, may offer cosmetic benefits for androgenetic alopecia; however, evidence is limited by small study sizes, varied methods, and short follow-up periods, necessitating standardized trials for routine use recommendations.

In this study, researchers developed a new microneedle patch delivery system for minoxidil, which enhanced its controlled release and improved hair growth in mice, potentially offering better treatment outcomes for androgenetic alopecia.

This review identifies headache, hypertrichosis, and allergy as potential side effects of Minoxidil treatment for hair loss, based on only two studies that met inclusion criteria.

This study found that injectable platelet-rich fibrin significantly improved hair growth and patient satisfaction as a cost-effective adjuvant treatment for androgenetic alopecia.

This study found that injectable platelet-rich fibrin (iPRF) combined with microneedling is a safe and effective treatment for male androgenetic alopecia, but it currently lacks comparison data against other popular therapies.

This case report suggests that long-acting injectable risperidone may induce hirsutism in some patients, and clinicians should monitor for this potential side effect when prescribing this antipsychotic.

Scalp Roller therapy helped improve hair growth in patients with hard-to-treat alopecia areata.

In this study, a combination therapy involving oral finasteride, oral and topical minoxidil, and injectable treatments led to significant improvements in hair growth for Asian men with androgenetic alopecia, with high patient satisfaction and minimal complications over a period of 6 to 12 months.

This study reported significant improvements in female pattern hair loss through a combination therapy involving spironolactone, minoxidil, and an injectable treatment over 6 to 12 months, with 95-96% patient satisfaction and minimal complications such as slight pain and hair growth in undesirable areas.

This review discusses prevention, diagnosis, and treatment strategies for traction alopecia but presents no new clinical findings; the authors emphasize early intervention to prevent permanent hair loss.

This abstract discusses advancements in hair transplantation technology, highlighting the role of robotics and follicular unit extraction/grafting in achieving excellent clinical outcomes, with adjuvant treatments like platelet-rich plasma, lasers, and stem cells potentially improving the durability and appearance of results.

This systematic review discusses various topical, oral, injectable, and non-pharmacological treatments for androgenetic alopecia, examining both current and emerging therapeutic options in addressing this common form of hair loss.

In a testosterone-induced mouse model, this study found that exosomes from injectable Platelet-Rich Fibrin (i-PRF) significantly reduced inflammation, oxidative stress, and apoptosis, while enhancing hair regeneration, with the greatest improvements seen when combined with minoxidil, suggesting potential as a novel treatment for androgenetic alopecia.

This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.

This study found that PRP treatment showed better results than injectable minoxidil for reducing hair loss and promoting hair growth, with noticeable effects after the second application.

This expert group provided recommendations for preparing and using platelet-rich plasma in treating androgenetic alopecia, suggesting a manual double-spin method and specific dosing, although further studies on injectable platelet-rich fibrin are needed.

This study found that a novel bioengineered microneedle patch successfully delivered minoxidil to induce hair growth in a mouse model, suggesting a promising approach to improve treatment for androgenetic alopecia.

This source reports that topical minoxidil effectively treats hair loss in androgenetic alopecia, varying efficacy by ethnic groups, and when combined with other therapies, shows increased effectiveness for conditions like alopecia areata and congenital hair disorders.

This review reports that pressure-induced alopecias, occurring from ischemic pressure, are often reversible without treatment if diagnosed promptly, but prognosis varies with severity and treatment timing.

Botulinum toxin may help hair loss by increasing blood flow and reducing harmful factors.

This review examines the psychological impacts of androgenic alopecia on women and evaluates existing treatment methods, highlighting the need for more effective and accessible therapeutic approaches.

This study discusses the role of physicians and pharmaceutical companies as entrepreneurial actors in off-label drug use, arguing they may advance patient care more quickly than regulatory agencies.

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.